You are here: Industry Insights > Celgene

News List

Sutro, Celgene to Refocus 2014 Immuno-Oncology Collaboration americanpharmaceuticalreview
August 11, 2017
Sutro Biopharma announced it is refocusing its 2014 immuno-oncology collaboration with Celgene on four programs that are advancing through preclinical development, including an antibody drug conjugate (ADC) program targeting B-Cell maturation antigen (BCM
Green light for Celgene’s targeted AML drug pharmatimes
August 03, 2017
US regulators have issued a green light for Celgene and Agios’ Idhifa, the first and only targeted treatment for adult patients with relapsed/refractory acute myeloid leukaemia and an isocitrate dehydrogenase-2 mutation
Celgene hopes device + drug can tackle aggressive brain tumours pharmaphorum
July 27, 2017
Celgene aims to boost the effectiveness of its novel drug marizomib for aggressive brain tumour glioblastoma (GBM) by asking patients to wear a special cap.
Celgene to acquire rights to BeiGene’s PD-1 inhibitor for solid tumour cancers pharmaceutical-technology
July 10, 2017
Celgene has entered a strategic collaboration to manufacture and market BeiGene’s protein 1 (PD-1) inhibitor, BGB-A317, for the treatment of patients with solid tumour cancers.
Celgene, Dragonfly Enter Strategic TriNKET Paltform Pact contractpharma
June 13, 2017
Aims to discover and develop Natural Killer Cell-Based Immunotherapies
Oral OTEZLA demonstrated significant improvement versus Placebo in clinical trial biospectrumasia
March 15, 2017
OTEZLA demonstrated significant improvements versus placebo for the primary and key secondary endpoints at week 16; Safety profile for OTEZLA in UNVEIL was consistent with that of previous trials
FDA Accepts New Drug Application and Grants Priority Review for Enasidenib in Relapsed or Refractory drugs.com
March 07, 2017
Celgene Corporation and Agios Pharmaceuticals today announced that the U.S. Food and Drug Administration (FDA) has accepted Celgene's New Drug Application.
EU expands use of Revlimid to include post ACST use pharmatimes
February 28, 2017
European regulators have expanded the scope of Celgene's Revlimid to include its use as monotherapy for the maintenance treatment of adults with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation (ASCT).
Executive Moves at Celgene contractpharma
February 27, 2017
Smith succeeds Fouse as president and COO
Celgene raises profit, revenue forecasts for 2017 firstwordpharma
January 10, 2017
Celgene on Monday announced that it was boosting its full-year profit forecast to the range of $7.10 per share to $7.25 per share...

Previous page 1 2 3 4 5 6 7 8 9 10 11 Next page